Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  High-risk Non-muscle Invasive Bladder Cancer
• Age: Between 18 Year(s) - 100 Year(s)
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1) Have histologically confirmed by BICR diagnosis of high-risk non-muscle invasive. 2) Have been treated with one adequate course of BCG induction therapy for the treatment of HR NMIBC defined as at least 5 intravesical instillations of BCG within a 10-week period of time. 3) Have undergone cystoscopy/TURBT to remove all resectable disease within 12 weeks prior to randomization.
  

You may not be eligible for this study if the following are true:

• 1) Has persistent (remains present or occurs within 3 months (–2 weeks) to 6 months (+4 weeks) after start of BCG induction) T1 disease following an induction course of BCG. 2) Women of child bearing potential who has a positive urine pregnancy test within 72 hours prior to randomization. 3) Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).